Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Evaluate Ltd., the leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry, is delighted to announce today that it has…
Stock market gains and dealmaking activity in Q4 clinched the biopharma sector’s strong performance in 2019 – a stark reversal of the declines seen in the final months of…
Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Vantage…
Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2019
Evaluate Ltd. releases annual “EvaluateMedtech World Preview 2018, Outlook to 2024” in conjunction with The Medtech Conference
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
Eleventh annual EvaluatePharma World Preview 2018, Outlook to 2024 report launches at BIO 2018.
Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.
EP Vantage releases its annual analysis of sector performance: Pharma, Biotech and Medtech 2017 in Review.
EP Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2018.
EvaluateMedTech Report Launches in Conjunction with The MedTech Conference.
EP Vantage Releases Half-Year Reviews of Pharma & Biotech and Medtech Performance.